PLAQUE PSORIASIS

This study tested a daily pill called apremilast in 203 Chinese adults with moderate to severe plaque psoriasis. Participants took either the drug or a placebo for 16 weeks. The main goal was to see if the drug could reduce psoriasis severity by at least 75%. This is a disease co…

This study tested a gel called SGX302 (synthetic hypericin) combined with visible light to treat mild-to-moderate psoriasis. 15 adults with plaque psoriasis applied the gel to their skin and received light therapy over 18 weeks. The goal was to see if the treatment could clear or…

This study tested a higher dose (10 mg/kg every 8 weeks) of the drug TA-650 in 51 adults with psoriasis whose symptoms had returned after initially responding to the standard dose of Remicade. The goal was to see if the higher dose could again improve skin symptoms. The study mea…

This study tested an experimental drug called TQH3906 in 209 adults with moderate to severe plaque psoriasis. The goal was to see if the drug could safely improve skin symptoms, like redness and scaling, after 12 weeks of treatment. Researchers measured how many patients achieved…

This study tested an experimental drug, JNJ-77242113, in 255 adults with moderate-to-severe plaque psoriasis. The goal was to see if different doses could improve skin symptoms, like redness and scaling, after 16 weeks of treatment. Participants were randomly assigned to receive …

This study tested the drug guselkumab in 213 adults with skin of color who have moderate-to-severe plaque or scalp psoriasis. Participants received either the drug or a placebo, and researchers measured how much their psoriasis cleared up after 16 weeks. The goal was to see if gu…

This study tested an experimental oral tablet, JNJ-77242113, in 90 adults with moderate-to-severe plaque psoriasis. Participants took the tablet or a placebo for 16 weeks. The main goal was to see if the drug could reduce psoriasis severity by at least 75% compared to placebo. Th…

This study tested an experimental drug called JNJ-77242113 in 227 adults with moderate-to-severe plaque psoriasis. The goal was to see how well the drug worked over the long term. After 36 weeks, many participants had significant skin clearing, as measured by standard psoriasis s…

This study tested a new drug, netakimab, in 202 Chinese adults with moderate to severe plaque psoriasis. Participants received either netakimab or a placebo to see if the drug could improve skin symptoms. The main goal was to measure how many people achieved at least a 75% improv…

This study tested an experimental drug called D-2570 in 161 adults with moderate-to-severe plaque psoriasis. Participants received either the drug or a placebo for 12 weeks. The main goal was to see if the drug could clear at least 75% of skin plaques. This is a disease-control s…

This study tested an experimental drug called LY4100511 in 222 adults with moderate-to-severe plaque psoriasis. Participants stopped other psoriasis treatments and received either the drug or a placebo. The main goal was to see how well the drug cleared skin and if it was safe. R…

This study tested a drug called bimekizumab in 60 adults with moderate-to-severe plaque psoriasis who had not gotten better with other similar treatments (IL-17 or IL-23 blockers). The goal was to see if bimekizumab could safely clear skin symptoms by targeting inflammation. Part…

This study tested whether a daily pill called ESK-001 can reduce psoriasis severity in adults with moderate to severe plaque psoriasis. Over 900 participants took ESK-001, a placebo (dummy pill), or an approved psoriasis drug (apremilast) for 24 weeks. Researchers measured skin c…

This study looked at how well and how safely a biosimilar drug called QLETLI (adalimumab) works for children and teenagers aged 4 to 17 with severe plaque psoriasis. 80 participants were treated and monitored for 24 weeks. The main goal was to see if the drug could significantly …

This observational study followed 331 adults with moderate to severe plaque psoriasis who were treated with tildrakizumab (Ilumetri®) in routine clinical practice. Researchers measured skin clearance (using PASI scores) and quality of life over up to 2 years. The goal was to see …

This study looked at whether switching from a lower to a higher concentration of adalimumab (AVT-02) reduces injection site pain and improves treatment adherence. It involved 324 adults with conditions like Crohn's disease, rheumatoid arthritis, or psoriasis. Researchers measured…

This study tested a cream called tapinarof on 575 adults with plaque psoriasis, a skin condition causing red, scaly patches. The goal was to see if the cream safely clears the skin better than a placebo. Participants used the cream daily for a set time, and doctors checked for im…

This study tested a new medication called TAK-279 in 693 adults with moderate-to-severe plaque psoriasis. Participants received either TAK-279, an approved drug (apremilast), or a placebo for up to 61 weeks. The main goal was to see if TAK-279 could clear or nearly clear skin pla…

This study tested a new drug called AX-158 in 31 adults with mild to moderate plaque psoriasis. Participants took either the drug or a placebo for 28 days, then were monitored for 30 more days to check safety. The main goal was to see if the drug is safe and tolerable, with some …

This study tested an experimental oral drug called LY3972406 in 33 adults with moderate-to-severe plaque psoriasis. The goal was to see if the drug could safely reduce skin redness, thickness, and scaling by at least 75% compared to a placebo. The trial is now complete, and resul…

This study involved 291 adults with mild-to-moderate scalp psoriasis who used a prescription cream (CAL/BDP PAD cream). Researchers measured how satisfied patients were with the treatment, its effect on their quality of life, and how well it worked in everyday use. The goal was t…

This study tested an experimental pill called TAK-279 in over 1,100 adults with moderate-to-severe plaque psoriasis. The goal was to see if it could clear or nearly clear skin plaques better than a placebo or an existing medication. Participants took TAK-279, an approved drug (ap…

This study tested a new daily pill, ESK-001, in 862 adults with moderate to severe plaque psoriasis. The goal was to see if it reduces skin symptoms like redness and scaling better than a placebo or an existing drug. Participants took the pill for 24 weeks and had regular checkup…

This early-stage study tested a new drug called CAN10 in 80 people to see if it is safe and how the body handles it. First, healthy volunteers received a single dose. Then, people with mild to moderate plaque psoriasis received multiple doses. The goal was to check for side effec…

This study tested whether an artificial intelligence (AI) tool could help doctors more accurately diagnose rare and tricky skin conditions like generalized pustular psoriasis (GPP). Fifteen general practitioners and dermatologists reviewed 100 skin images, first giving their own …

This study tested whether an artificial intelligence (AI) tool could help primary care doctors more accurately diagnose skin conditions like melanoma, psoriasis, and eczema. Nine doctors reviewed 30 skin images, first giving a diagnosis on their own, then with the AI's suggestion…

This study tested whether digital photographs can reliably measure psoriasis severity compared to in-person exams. Thirty-four adults with plaque psoriasis had their skin scored both ways. The goal was to see if remote assessments could be trusted for future research or care.